Bridging the Valley of Death of therapeutics for neurodegeneration | Zendy

Steven Finkbeiner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bridging the Valley of Death of therapeutics for neurodegeneration

Author(s) -

Steven Finkbeiner

Publication year - 2010

Publication title -

nature medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.536

H-Index - 547

eISSN - 1546-170X

pISSN - 1078-8956

DOI - 10.1038/nm.2222

Subject(s) - neurodegeneration , disease , drug development , warrant , bridging (networking) , clinical trial , medicine , intensive care medicine , drug , business , pharmacology , pathology , computer science , computer network , finance

Neurodegenerative diseases are the sixth leading cause of death in the US. The market for disease-modifying drugs is enormous, but no drug exists. Academic scientists are increasingly pursuing the discovery and development of therapeutics. Their progress could potentially reduce the risk of failure sufficiently to warrant greater industry investment and movement of leads into clinical trials. Here we consider the many obstacles to the development of therapeutics for neurodegenerative disease within academia, with a special focus on organizational issues.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research